Global Continuous Glucose Monitoring System, by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Size, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 – 2021
"Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share.
However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for paediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers.
Chap 1. Executive Summary
Chap 2. Market Overview
2.1. What ARE CGMS?
2.2. Value Chain Analysis of the role of suppler, manufacturer, and end user in the CGMS market
2.2.1. Suppliers enabling financially weak players
2.2.2. Manufacturers facing regulations and operational cost issues
2.2.3. Pediatrics and hospitals will lead the future market growth
2.3. Key Buying Criteria
2.3.1. Convenience factor
2.3.2. Price is the key concern
2.3.3. Improved Accuracy leads to easier regulation norms
2.3.4. Collaboration of the two main manufacturers
2.3.5. Development of durable sensors
2.3.6. Development of APD
2.3.7. Focus on developing Asian markets
2.3.8. Partnerships and Collaborations – the winning strategies
2.3.9. Innovation Important for new entrants
Chap 3. Market Determinants
3.1. CGMS Market Motivators
3.1.1. Diabetes population rise leads to larger market opportunity
3.1.2. Rise in the global health expenditure and emerging Asian Market
3.1.3. Increased R&D funding for faster approvals and development of APD
3.1.4. Insulin Pump manufacturers willing to integrate CGMS and insulin pump technology
3.1.5. Private Insurers INCREASING CGMS AFFORDABILITY
3.1.6. New technology can bring down prices
3.2. RESTRAINTS
3.2.1. Government Regulations delaying the processes
3.2.2. Established SMBG DEVICE manufacturers restraining CGMS growth
3.2.3. Poor access to the healthcare services in developing markets
3.3. Opportunities
3.3.1. Growing diabetic population
3.3.2. Emergence of new segment - Pediatrics
3.3.3. Case study on pediatrics use
3.3.4. Development of artificial pancreas
3.4. Challenges in CGMS market
3.4.1. High Price
3.4.2. Unmet Diabetic needs
3.4.3. No government aid makes it difficult for the consumer
Chap 4. Sector Analysis: Diabetes Care
Chap 5. CGMS Market By devices
5.1. Long lasting Sensors: the need of the hour
5.1.1. Factors influencing CGM sensor development
5.2. Transmitters and receivers - The standalone system
5.2.1. Price the major restraint for transmitters and receivers
5.3. Insulin Pumps hold the future
5.3.1. Innovation and Collaboration the mainstay for insulin pumps
Chap 6. By Application
6.1. Professional CGMS (used by healthcare professionals)
6.1.1. Professional CGMS types
6.1.2. Case study on use of CGMS in hospital settings
6.1.3. Case study 2:Medtronic Real Time CGMS in rural Settings
6.1.4. Personal CGMS segmented on the basis of Age groups
Chap 7. Competitive Intelligence
7.1. Key Strategies to help CGMS market drive acceptance
7.1.1. Innovation The Key Industry to Overcome Competition
7.1.2. Technology Leveraging - Key focus of partnerships Among industry players
7.1.2.1. Key objective of partnerships and agreements in the CGMS market
7.1.2.2. Major agreements signed by CGMS manufacturers since 2007
7.1.3. Product Launch - a make or break marketing strategy
7.1.3.1. Recent product launches
7.1.4. Acquisitions Still Remain Niche in the CGMS Market
Chap 8. Market Share Analysis
8.1. Key Company Analysis
8.1.1. Dexcom
8.1.2. Medtronic
8.1.3. Abbott Diabetic Care
8.1.4. Market Share
8.1.5. Conclusion
Chap 9. Geographical Analysis
9.1. North America
9.1.1. United States of America
9.1.1.1. A developed economy a Major business driver
9.1.1.2. Awareness is the key to CGMS adoption
9.1.1.3. Medicare and reimbursements are the future drivers
9.1.1.4. High number of T1D
9.1.1.5. Regulations Obstructing market expansion
9.1.1.5.1. US FDA guidelines for the development of artificial pancreas
9.1.1.5.1.1. Primary components of an APD
9.1.1.5.1.2. Secondary component
9.1.1.6. Key Market Players in the US
9.2. Canada
9.2.1. Regulations in Canada
9.3. Europe
9.3.1. European Union (EU)
9.3.1.1. THE UK 87
9.3.1.1.1. Regulations in the UK
9.3.1.1.2. Key companies in the UK
9.3.1.2. France
9.3.1.3. Germany
9.3.1.4. CGMS business in the EU
9.4. Asia Pacific
9.4.1. China
9.4.1.1. Regulations in China
9.4.2. India
9.4.2.1. Regulation in India
9.4.2.2. CGMS in India
9.4.3. Australia
9.4.3.1.1. Regulations in Australia
9.5. Latin America
9.5.1. Factsheet of diabetes statistics in Latin America
9.5.1.1. Brazil
9.5.1.2. Argentina
9.5.1.3. Mexico
9.5.2. Rest of the World
9.5.2.1. Middle-East and North Africa
9.5.2.2. Africa
Chap 10. Corporate Profile: Benchmark Study
10.1. Medtronic Inc.
10.1.1. Business Profile
10.1.2. Product Portfolio
10.1.3. Revenue Analysis
10.1.4. Strategic Inputs
10.2. Dexcom
10.2.1. Location
10.2.2. Business Profile
10.2.3. Product Portfolio
10.2.4. Revenue Analysis
10.2.5. Strategic inputs
10.3. Abbott
10.3.1. Locations
10.3.2. Business Profile
10.3.3. Product Portfolio
10.3.4. Revenue Analysis
10.3.5. Strategic inputs
10.4. Johnson and Johnson (J&J) (Animas Corp)
10.4.1. Locations
10.4.2. Business Portfolio
10.4.3. Product Portfolio
10.4.4. Revenue Analysis
10.5. Insulet Corp
10.5.1. Geography
10.5.2. Business Portfolio
10.5.3. Product Portfolio
10.5.4. Revenue Analysis
10.5.5. Strategic inputs
10.6. Tandem Diabetes
10.6.1. Business Portfolio
10.6.2. Revenue Analysis
10.7. Echo Therapeutics
10.7.1. Business Portfolio
10.7.2. Product Portfolio
10.7.3. Revenue Analysis
Table List
TABLE 1 Summary table: Global CGMS market, 2013-2021 (USDmillion)
TABLE 2 Comparison of price of SMBG and CGM (US)
TABLE 3 Comparative prices of sensors and test strips (based on various online retail prices)
TABLE 4 Ratio (Physician per 1,000 people)
TABLE 5 Comparison of price (US)
TABLE 6 CGM market by device (2013-20)
TABLE 7 Cost Of sensors (in USD)
TABLE 8 Cost of Transmitters and Receivers (in USD)
TABLE 9 Cost of insulin pumps (in USD)
TABLE 10 CGM market by application (2013-2021)
TABLE 11 Global CGMS by age market (2013-2021), in USD million
TABLE 12 Devices approved for pediatric use
TABLE 13 Revenue by Geography (2013-2021)
TABLE 14 Diabetes Statistics
TABLE 15 French Diabetic Statistics
TABLE 16 Germany Diabetic Statistics
TABLE 17 China Diabetes Statistics
TABLE 18 Statistics for diabetes in India
TABLE 19 Statistics for diabetes Australia
TABLE 20 Life expectancy in Latin America
TABLE 21 Total revenue (Geography; 2013)
TABLE 22 Revenue (Segment wise; 2013)
TABLE 23 Revenue (Segment wise; 2013)
Figures List
FIGURE 1 Key Buying Criteria 2013 versus 2021
FIGURE 2 2013 GDP of top 10 Asian Countries (USD billion)
FIGURE 3 Diabetic Population, 2013 (in millions)
FIGURE 4 Per Capita income comparison (in USD)
FIGURE 5 SmartPhone technology
FIGURE 6 Process of obtaining a market approval through FDA
FIGURE 7 global Sensor market revenue (2013-2021) (USD million)
FIGURE 8 global Transmitters and receivers market (2013-2021), in USD million
FIGURE 9 global Insulin Pumps market (2013-2021), in USD million
FIGURE 10 Global CGMS for Diagnostics and Clinics (2013-2021), in USD million
FIGURE 11 Global CGMS for Hospitals (2013-2021), in USD million
FIGURE 12 Global CGMS in Home settings (2013-2021), in USD million
FIGURE 13 Global CGM for pediatric market (2013-2021), USD million
FIGURE 14 Intra relationship of strategies
FIGURE 15 Medtronic’s Product development timeline
FIGURE 16 Dexcom Inc Revenue (In million USD)
FIGURE 17 Medtronic Diabetes -Revenue (In million USD)
FIGURE 18 Market Share
FIGURE 19 Percentage share (geography)
FIGURE 20 North America, 2013-2021, in USD million
FIGURE 21 The US (2013-2021), in USD million
FIGURE 22 Age standardized prevalence of Diabetes in Aboriginals and Non Aboriginals
FIGURE 23 Canada. 2013-2021, in USD million
FIGURE 24 Europe, 2013-2021
FIGURE 25 Data on diabetic population in Europe
FIGURE 26 THE UK, 2013-2021
FIGURE 27 France, 2013-2021
FIGURE 28 Germany, 2013-2021
FIGURE 29 Asia Pacific, 2013-2021
FIGURE 30 China, 2013-2021
FIGURE 31 India (2013-2021)
FIGURE 32 Australia (2013-2021)
FIGURE 33 Process of supplying a medical device in Australia for an overseas manufacturer
FIGURE 34 Latin American market, 2013-2021(USD million)
FIGURE 35 Life expectancy graph
FIGURE 36 Rest of the world (2013-2021)
FIGURE 37 Total revenue (Product mix; 2013)
FIGURE 38 Powerzone Mapping (Medtronic vs. Dexcom)
